{"entity":{"id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","aka":[],"tldr":"A phase 3 trial of Darolutamide in advanced solid tumours, run by Bayer, active and no longer recruiting.","summary":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer is a phase 3 interventional study registered as NCT04464226 by Bayer, with 402 participants enrolled, started 2020-10-20 and due to reach its primary completion in 2028-06-26. Interventions recorded: Darolutamide (Nubeqa, BAY1841788).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04464226","url":"https://clinicaltrials.gov/study/NCT04464226"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["androgen-deprivation"],"targets":[],"drugs":["darolutamide"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04464226","phase":"3","setting":"An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies","sponsor":"Bayer","participation":[{"nct":"NCT04464226","source":"https://clinicaltrials.gov/study/NCT04464226","fetchedAt":"2026-10-07T16:53:20.581Z","studySha256":"e11b2f63ca00c94b5c3700f24c7a824e81c331bba4dbabb8b3941c3ec96c325e","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-07","leadSponsor":"Bayer","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":402,"enrolmentType":"ESTIMATED","siteCount":335,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Belarus","Belgium","Brazil","Bulgaria","Canada","China","Colombia","Czechia","Estonia","Finland","France","Germany","Hungary","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2020-10-20","startedType":"actual","enrolled":402,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04464226/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"}],"drug":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}]}}